Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

Background Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue hu...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Pierpaolo Correale, Valerio Nardone, Pierpaolo Pastina, Pierosandro Tagliaferri, Luigi Pirtoli, Rita Emilena Saladino, Rocco Giannicola, Rita Agostino, Nicoletta Staropoli, Alessandra Strangio, Teresa Del Giudice, Maria Altomonte, Paolo Tini, Antonia Consuelo Falzea, Natale Imbesi, Valentina Arcati, Giuseppa Romeo, Daniele Caracciolo, Amalia Luce, Michele Caraglia, Antonio Giordano, Alois Necas, Evzen Amler, Vito Barbieri, Pierfrancesco Tassone
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMJ Publishing Group 2020-05-01
סדרה:	Journal for ImmunoTherapy of Cancer
גישה מקוונת:	https://jitc.bmj.com/content/8/1/e000733.full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!